Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.28 USD | +4.07% | 0.00% | +9.40% |
05-13 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
05-09 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.40% | 95.66M | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.64% | 21.25B | |
-5.61% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical : Wedbush Adjusts PT on Clearside Biomedical to $18 From $6 on CLS-AX Potential in Treating Wet Age-Related Macular Degeneration; Outperform Rating Kept